LZLinling Zhou

Linling Zhou

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Linling Zhou has a total of 11 co-authors. Here are the top co-authors by number of shared publications:

  • Liqiang Pan

    Laboratory of Precision Medicine and Biopharmaceuticals, School of Pharmacy, Zhejiang University, Hangzhou, China; Department of Pharmacy, the Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang University, Hangzhou, China; Institute of Fundamental and Transdisciplinary Research, Zhejiang University, Hangzhou, China

    2 shared publications
  • Jiaqi Zhao

    School of Pharmacy and Department of Pharmacy, The Second Affiliated Hospital, Zhejiang University, Hangzhou 310058, China

    1 shared publication
  • Jiaqi Zhao

    Department of Pharmacy, the Second Affiliated Hospital, School of Medicine and College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China

    1 shared publication
  • Jie Bi

    School of Pharmacy and Department of Pharmacy, The Second Affiliated Hospital, Zhejiang University, Hangzhou 310058, China

    1 shared publication
  • Jie Bi

    Department of Pharmacy, the Second Affiliated Hospital, School of Medicine and College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China

    1 shared publication
  • Jisheng Wang

    The Third Hospital of Mianyang (Sichuan Mental Health center), Mianyang 612000, China

    1 shared publication

Latest Publications

  • Open Access

    APRIL-driven BCMA/TACI dual-targeted ligand–drug conjugates for selective and potent therapy of multiple myeloma

    by Linling Zhou, Yanping Sun, Jie Bi, Jiaqi Zhao, Yinli Xia, Jun He, Jisheng Wang, Liqiang Pan


  • Open Access

    Leveraging T cell co-stimulation for enhanced therapeutic efficacy of trispecific antibodies targeting prostate cancer

    by Yanping Sun, Linling Zhou, Xinyu Gu, Jiaqi Zhao, Jie Bi, Liqiang Pan

    Background: Clinical trials have demonstrated the efficacy of bispecific antibodies in eliciting potent antitumor responses by redirecting T cells to target cancer cells, particularly for the treatment of hematologic malignancies. However, their efficacy against solid tumors is limited by intratumoral T-cell dysfunction and inadequate persistence. The co-stimulatory domains of 4-1BB, OX40, and CD28 are most widely used in engineering chimeric antigen receptor T-cells to augment T-cell responses. Methods: In this study, we designed three co-stimulatory trispecific T cell-engaging antibodies (TriTCEs) that target Prostate-specific membrane antigen, CD3, and an additional co-stimulatory receptor(OX40, 4-1BB, or CD28). We conducted comparative profiling of the attributes of distinct co-stimulatory signals to T-cell functions in prostate cancer models. Results: Co-stimulatory trispecific T-cell engagers enhance T-cell activation, proliferation, and display tumor cell-killing activity in vitro. These trispecific antibodies further boosted antitumor activity in humanized mouse xenograft models and increased the infiltration of CD45+ immune cells into solid tumors. Specifically, TriTCE-4-1BB and TriTCE-CD28 selectively promoted the expansion of effector memory T cells and increased the presence of CD4+ T cells more than TriTCE-OX40. T cells stimulated with TriTCE-4-1BB exhibited reduced exhaustion. Furthermore, T cells treated with co-stimulatory trispecific antibodies demonstrated enhanced metabolic activity characterized by increased oxidative phosphorylation and elevated glycolysis. Conclusions: Collectively, incorporating co-stimulatory receptor targeting domains represents a potentially effective strategy to unlock the full therapeutic potential of T-cell-engaging antibodies for the treatment of solid tumors.